Evaluation of Therapeutic Efficacy of Adjustable Mandibular Advancement Device in the Management of Obstructive Sleep Apnea

Amit Bansal, B Jayan, Prasanna Kumar MP, Mohit Sharma, Sunil Kumar

ABSTRACT

Introduction: Medical dental sleep appliance (MDSA) is an adjustable mandibular advancement device (MAD) recommended for treatment of snoring and obstructive sleep apnea (OSA). There are very few studies on Indian population which evaluate the therapeutic efficacy of mandibular advancement devices in the management of OSA.

Materials and Methods: A prospective clinical study was carried out. Twenty polysomnography diagnosed OSA patients fulfilling the inclusion and exclusion criteria were treated with MDSA and changes in pre and post-treatment sleep para-meters (apnea-hypopnea index (AHI) and epworth sleepiness scale (ESS)) were recorded.

Results: Mean differences in pre- (T1 = 30.7 ± 5.0) and post-treatment (T2 = 17.2 ± 3.9) AHI values and ESS pre-treatment (T1 = 17.2 ± 0.6) and post-treatment (T2 = 10.9 ± 0.9) were highly statistically significant (p < 0.001). Clinically the maximum improvement was observed in mild and moderate OSA cases. Although significant clinical improvement was also observed in severe OSA cases, the post-treatment AHI and ESS were still high.

Conclusion: MDSA is a non-invasive, low risk and cost-effective treatment option for patients suffering from mild and moderate obstructive sleep apnea and also in cases of severe OSA who are not comfortable with CPAP or not willing for surgery.

Keywords: AHI, ESS, MDSA, OSA

How to cite this article: Bansal A, Jayan B, Kumar PMP, Sharma M, Kumar S. Evaluation of Therapeutic Efficacy of Adjustable Mandibular Advancement Device in the Management of Obstructive Sleep Apnea. Indian Sleep Med 2018;13(1):5-12.

Source of support: Nil

Conflict of interest: None

INTRODUCTION

Obstructive Sleep Apnea (OSA) is a condition that results due to partial or complete obstruction of airway when patient assumes a supine position and goes to sleep. In the last three decades, mandibular advancement devices (MAD) have been used to treat OSA. MADs move the mandible forward to improve upper airway patency and are the most evaluated type of appliances. An influential review of oral appliance (OA) therapy for OSA, accompanied by practice parameters of American Sleep Disorder Association signaled the entry of dentistry into mainstream sleep medicine. Adjustable mandibular advancement appliance became predominant form of dental therapy for sleep-disordered breathing since the 1990s. Controlled studies in the last decade and a half have shown effectiveness and preference for oral appliances compared to Continuous Positive Air Pressure (CPAP) in mild and moderate cases. Studies have also reported gross improvement in severe cases if patient selection is based on stringent inclusion criteria.

MADs have shown to significantly improve objective parameters, such as AHI, arousal index, snoring and arterial oxygenation. They have shown to improve quality of life, blood pressure and improvements in cardiovascular outcomes and inflammatory markers similar to CPAP.

There are several designs of adjustable mandibular advancement devices for OSA patients but there is no consensus on the design of adjustable MAD. Medical Dental Sleep Appliance is an adjustable MAD and a third generation intraoral dental device recommended for treatment of snoring and OSA. It is readily available in India and one of the most cost-effective appliances, custom fabricated in the dental laboratory.

There are very few studies on Indian population which evaluate the therapeutic efficacy of mandibular advancement devices in the management of OSA. In view of the above, it was proposed to evaluate the therapeutic efficacy of medical dental sleep appliance, an adjustable MAD in the management of OSA objectively and subjectively. To evaluate the therapeutic efficacy of MDSA, an adjustable MAD, in the management of OSA by testing the null hypothesis that there is no difference in pre- and post-treatment sleep parameters in patients treated with MDSA.

The objectives of the study were:-
● To compare baseline and post-treatment apnea-hypopnea index (AHI) scores.
● To compare baseline and post-treatment epworth sleepiness scale (ESS).

MATERIALS AND METHODS

A prospective clinical study was carried out at the Department of Orthodontics and Dentofacial Orthopedics of Armed Forces Medical College, Pune. Twenty polysomnography diagnosed obstructive sleep apnea patients referred from Dept of Pulmonary and Sleep Medicine, Military Hospital (CTC), Pune and Dept of Otorhinolaryngology, Armed Forces Medical College, Pune, fulfilling the inclusion and exclusion criteria were inducted for the study.

Inclusion Criteria

● PSG diagnosed adult OSA cases (mild, moderate OSA cases and severe OSA cases not amenable to CPAP therapy or surgery).
● BMI <30 kg/m²
● Any of the following two findings on the lateral cephalogram
  ● SNB <78°
  ● MPH (Hyoid distance) >15 mm
  ● Angle ANB >4°
  ● Posterior airway space (linear distance from the posterior border of the tongue to pharyngeal wall measured along the B-Go line) <10 mm
  ● Minimum mandibular protrusion of 5 mm
  ● Minimum interincisal opening of 35 mm

Exclusion Criteria

● Central sleep apnea
● Mixed sleep apnea
● Severe accompanying respiratory disorders
● Advanced periodontal disease
● Partial edentulous cases (<14 healthy permanent teeth)
● Adenotonsillar hypertrophy, septal deviation, turbinate hypertrophy or nasal polyp

Sample Size Calculation

The sample size was calculated for one-tailed hypothesis testing for the hypothesis $H_0$: $\mu_1-\mu_2 = 0$ against $H_1$: $\mu_1-\mu_2 < 0$ with $\alpha = 0.05$ (5%) and $\beta = 0.80$ (80%). Pre and Post AHI and ESS scores (based on data from reference no. 6) were as follows:

<table>
<thead>
<tr>
<th>S. No</th>
<th>Parameter</th>
<th>Pre Mean</th>
<th>Pre SD</th>
<th>Post Mean</th>
<th>Post SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>AHI</td>
<td>47.63</td>
<td>7.93</td>
<td>20.61</td>
<td>5.78</td>
</tr>
<tr>
<td>2</td>
<td>ESS</td>
<td>12.70</td>
<td>1.82</td>
<td>8.50</td>
<td>1.26</td>
</tr>
</tbody>
</table>

Thus, minimum sample size required works out to be 4 for data for AHI and 7 for data for ESS. In this study, 20 subjects were included.

Procedure Methodology

All the study subjects were subjected to lateral cephalometric roentenography as per standard protocol. Lateral cephalograms were recorded at end expiration and the patients were asked not to deglute/swallow during the process of radiography. All the radiographs were traced by a single operator and five lateral cephalograms were retraced after one week by the same operator to rule out any discrepancies.

Data collection was divided into two sections as follows:

Sleep-disordered breathing form was used to record the medical and sleep history including an ESS. Using this scale, the subjects were asked to rate, on a scale of 0-3, how likely they were to doze off or fall asleep in each of the eight different situations. In the ESS, a 4-point scoring scale was used as under:

• 0 = would never doze
• 1 = slight chance of dozing
• 2 = moderate chance of dozing
• 3 = high chance of dozing

The ESS was recorded pretreatment and again post-treatment after assessment of subjective improvement.

Baseline and post-treatment polysomnography (PSG) was utilized for AHI.

Patients meeting the selection criteria were taken up for treatment with the Medical Dental Sleep Appliance (MDSA Pty Ltd, Australia) (Figs 1 and 2), an adjustable mandibular advancement device. Titration was done with a key provided in the kit depending on subjective improvement. Titration did not exceed 70% of maximum protrusion. The patients were recalled weekly to ascertain subjective improvement in sleep parameters. After ascertaining subjective response from the patient or bed partner in terms of reduction/cessation of snoring, excessive day time sleepiness and regularity in use of the prescribed appliance, the patient was subjected to recording of ESS and PSG with MDSA in situ. The patient was observed for discomfort in the TMJ area or teeth, excessive salivation or any other appliance related problems.
The mean $\pm$ SD for pretreatment AHI for the group was calculated to be 30.7 $\pm$ 5.0 as shown in Table 2. Seven cases (35.0%) had mild OSA (AHI = 5-15 events/hr), five cases (25.0%) had moderate OSA (AHI = 15-30 events/hr) and eight cases (40%) had severe OSA (AHI > 30 events/hr).

Out of the 20 cases studied, 6 cases (30.0%) had a BMI between 18.5 to 24.9 (Healthy category) and 14 cases (70.0%) had a BMI between 25.0 to 29.9 (Overweight category). The mean $\pm$ SD of BMI of the entire group of cases was 26.5 $\pm$ 2.2 kg/m$^2$.

**Descriptive Statistics for Pre- and Post-treatment Variables**

To identify the significance of post-operative changes with respect to pre-operative values, a Student’s paired t-test was used for all pre and post AHI and pre and post ESS after confirming the underlying normality assumption using the Shapiro–Wilk’s test.

Results of comparison for AHI pre- ($T_1 = 30.7 \pm 5.0$) and post-treatment ($T_2 = 17.2 \pm 3.9$) values show an average change in $T_2$ values of 13.5 which is highly statistically significant ($p < 0.001$).

Comparison for ESS pre- ($T_1 = 17.2 \pm 0.6$) and post-treatment ($T_2 = 10.9 \pm 0.9$) values shows there is an average decrease of 6.3. This mean difference is highly statistically significant ($p < 0.001$) and shows the improvement in nighttime sleep quality and reduction in daytime sleepiness with MDSA.

For mild OSA cases, comparison for AHI pre- ($T_1 = 10.8 \pm 2.6$) and post-treatment ($T_2 = 4.5 \pm 3.9$) values show an average change in $T_2$ values of 6.4 which is statistically significant ($p < 0.005$) and ESS pre- ($T_1 = 15.0 \pm 2.24$) and post-treatment ($T_2 = 8.57 \pm 3.6$) values shows there is an average decrease of 6.43. This mean difference is extremely statistically significant ($p < 0.001$).

For moderate OSA cases, AHI pre-treatment ($T_1 = 21.8 \pm 4.1$) and post-treatment ($T_2 = 10.3 \pm 2.1$) values show an average change in $T_2$ values of 11.5 which is extremely statistically significant ($p < 0.001$) and ESS pre- ($T_1 = 17.0 \pm 1.2$) and post-treatment ($T_2 = 10.8 \pm 1.3$) values shows there is an average decrease of 6.2 which was again extremely statistically significant ($p < 0.001$).

AHI pre- ($T_1 = 53.5 \pm 17.2$) and post-treatment ($T_2 = 32.6 \pm 18.8$) values for severe OSA cases show an average change at $T_2$ of 20.9 which is statistically significant ($p < 0.005$) and ESS pre- ($T_1 = 19.1 \pm 2.8$) and post-treatment ($T_2 = 13.0 \pm 4.1$) values shows there is an average decrease of 6.1 which was again statistically highly significant ($p = 0.001$).

Clinically, it was observed that maximum improvement in snoring and daytime sleepiness was observed in mild and moderate OSA cases. Although significant
clinical improvement was also observed in severe OSA cases, the post-treatment AHI and ESS were still high.

Comparison of pre- and post-treatment AHI and ESS for the mean of differences for mild, moderate and severe OSA are presented in Graphs 1A to 1C.

Graph 1A: Comparison of pre- and post-treatment AHI and ESS (Mild OSA)

Graph 1B: Comparison of pre- and post-treatment AHI and ESS (Moderate OSA)

Adverse Effects of MDSA

Nine participants experienced increased salivation and difficulty in sleeping with the appliance in situ. However, these effects decreased gradually and most patients comfortably wore the appliance for the entire duration of sleep after 1 week of appliance delivery.
Hence, there is a major need for effective alternative treatment modalities. Custom made mandibular advancement devices are an effective treatment option for snoring, upper airway resistance syndrome and obstructive sleep apnea. Evidence-based data indicates their efficacy, and international sleep societies recommend oral appliance therapy for patients with sleep-related breathing disorders.1,10,12 The rationale behind the efficacy of MADs is that advancement of the mandible and tongue improves upper airway patency during sleep by enlarging the upper airway and by decreasing upper airway collapsibility, thereby preventing collapse during sleep.4 A mandibular advancement appliance should positively place the lower jaw in a predictable and maximally therapeutic position.

MDSA is a third generation two-piece appliance with separate components on maxilla and mandible. A separate component for each jaw makes fitting easier and makes it more difficult to dislodge because the removal of the appliance is in different path of opening.13 Connecting the upper and lower appliance is accomplished by a single hook and latch in the anterior region. Because of the versatility and ease of adaptation, the MDSA is more effective than the one piece appliance. The appliance design restricts all backward movements while still allowing the patient to move the mandible forward and side to side and open the mouth if necessary.

There are numerous studies highlighting the benefits of different mandibular advancement devices in OSA.3,5-7,14-33 However, a review on oral appliances therapy for OSA has pointed out that most studies exclude the patients with severe OSA, thus there exists a significant source of bias.11 Furthermore, only a few studies have studied the third generation adjustable MADs6,7,17,23-25,31 and only one study evaluated the efficacy of the medical-dental sleep appliance for the management of OSA.25 There is also a paucity of studies with regard to prescribing oral appliances with definite inclusion and exclusion criteria. Some studies have shown that if cephalometric findings like reduced posterior airway space/retroglossal space, increased hyoid-mandibular plane distance, retrusion mandible and BMI < 30 Kg/m² are considered, along with established dental norms for oral appliance therapy, 70% mandibular protrusion with MDSA can bring about desired therapeutic efficacy in severe OSA cases.6,7

Keeping these criteria in mind, this prospective clinical study was performed to assess the therapeutic efficacy of MDSA in the treatment of OSA.

**Sample Characteristics**

The study sample consisted of 20 subjects with 18
males (90%) and 2 females (10%). This gender bias was expected as female hormones have been shown to have a protective action against OSA in a review article by Banno and Kryger. They reported that progesterone, a female hormone, has respiratory stimulant properties while testosterone, a male hormone, has been reported to increase upper airway collapsibility, which may increase the risk for the development of OSAS. They also stated that due to the hormonal changes, the prevalence of OSAS in postmenopausal females is higher than in premenopausal females. This correlation was re-established in our study as both the female subjects reported to be post-menopausal.

The mean BMI of the study sample was 26.5 ± 2.2 kg/m². Only patients with BMI < 30 kg/m² were included in the study to rule out any confounding factor that may arise due to a positive correlation between increased BMI and severity of OSA as shown in various studies. These studies suggest that the shape and dimension of the pharyngeal lumen was more dependent on BMI than on the presence of OSA and a higher BMI was related to a more severe OSA.

The mean ± SD of baseline AHI for the group was 30.7 ± 5.0.

Seven cases (35.0%) had mild OSA, five cases (25.0%) had moderate OSA and eight cases (40%) had severe OSA who did not agree for surgery or were uncomfortable with CPAP. This was in agreement with scientific appraisals and international guidelines of different sleep societies which recommend oral appliance treatment for primary snoring, upper airway resistance syndrome, mild to moderate OSA (AHU up to 30/h) and in severe cases, not amenable to CPAP therapy.

**Therapeutic Effects of MDSA**

Due to strict adherence to the inclusion and exclusion criteria, we observed a highly significant improvement in AHI scores. The mean AHI scores decreased from 30.7 ± 5.0 to 17.2 ± 3.9. As per international norms, 50% reduction in AHI scores is considered successful treatment. We could not achieve the same in ten cases. This can be attributed to the fact that 8 cases (40%) of the study population treated had severe OSA (AHU > 30), where oral appliance therapy is not the first choice. However, the overall improvement in AHI scores in the study sample was highly statistically significant (p < 0.001). Ten cases in the present study showed more than 50% reduction in AHI scores.

In the present study, post-treatment AHI scores did not show significant difference in two cases (S.No 4 and 17 of Table 1). It is not clear as to why oral appliance were effective in most except two cases. Various individual anatomic factors, the degree of vertical and sagittal opening, the skeletal pattern of the skull and oropharyngeal tissue compliance may influence therapeutic efficacy, as reported in the literature. Patient compliance is another factor to be taken into consideration as the initial difficulties are experienced with appliance wear and sleep parameters may take some time to improve. Although constant motivation and counseling was carried out, some subjects tended to be impatient with the delay in response.

Clinically, most patients showed subjective improvement in the form of reduction in snoring, as reported by bed partner and decreased daytime sleepiness as assessed by the Epworth sleepiness scale. ESS scores reduced from 17.2 ± 0.6 to 10.9 ± 0.9 which was highly statistically significant (p < 0.001). Clinically these changes manifested as improved nighttime sleep quality with reduction in snoring and decreased daytime sleepiness. Decrease in snoring was reported almost immediately in all cases however the daytime sleepiness showed improvement over a period of 4-6 months. The time taken can be due to the ‘sleep debt’ caused due to the decreased nighttime sleep quality in OSA patients. However, in the two cases in which the AHI did not improve, there was no significant clinical improvement highlighting the proven correlation between AHI and ESS.

When these changes are correlated clinically it was observed that maximum improvement in snoring and day time sleepiness was observed in mild and moderate OSA cases. In severe OSA cases, although the significant clinical improvement was observed, the post-treatment AHI and ESS were still high in most cases. These findings are in agreement with a randomized controlled trial by Barnes et al who reported MDSA to be effective in the management of mild and moderate OSA. A prospective study by Marklund et al also demonstrated a significant reduction in AHI in patients with MADs in a wide range of OSA severities but the greatest improvement was observed in patients with mild and moderate cases. Similarly, a randomized clinical trial by Johnston et al concluded that mandibular advancement appliance was less effective in subjects with most severe OSA (pre-treatment AHI > 50). In a recent meta-analysis, Sharples and co-workers have shown that MAD results in a significant improvement in post-treatment AHI, and that the estimate of effect was similar irrespective of baseline AHI and the effect of MAD on subjective day time sleepiness measured using the ESS followed a similar pattern.

**Adverse Effects of MDSA**

All the participants were followed up for a minimum period of 6 months post appliance delivery to ascertain
any short-term side effects. Immediately after appliance delivery, nine participants experienced increased salivation and difficulty in sleeping with the appliance. However these effects decreased gradually in all but one patient, and they comfortably wore the appliance for the entire duration of sleep after one week of appliance delivery. Similar findings were reported by various studies in which over 80% of the patients reported some sort of adverse effect, mostly excessive salivation or dry mouth, that they attributed to the device.28,41,42

None of the patients showed any adverse effects in the dentition, in the form of changes in occlusion, or masticatory system in the form of pain and discomfort in TMJ due to wearing the MDSA over a 6 month period. Bondemark et al.43 compared masticatory system symptoms such as temporomandibular pain or clicking, headache, jaw muscle fatigue or soreness to baseline data or to a control group without mandibular repositioning appliances and reported no increase in the incidence of such symptoms. One long-term study by Almeida et al.44 showed a more marked change in overjet and overbite. However, another prospective long-term study by Marklund et al.45 did not show any further changes in occlusion. Literature suggests that these changes seemed to develop during the first few years of use of the device and then stabilize. None of the studies with a follow-up period of less than 6 months reported clinical signs of changes in occlusion.41,42

CONCLUSION

This prospective clinical study was conducted to evaluate the therapeutic efficacy of Medical Dental Sleep Appliance (MDSA), an adjustable mandibular advancement device, in the management of OSA by testing the null hypothesis that there is no difference in pre and post treatment sleep parameters in patients treated with MDSA. The following conclusions can be drawn from the study:

The null hypothesis is rejected as there is a highly significant difference in pre- and post-treatment sleep parameters, i.e., AHI and ESS scores, in patients treated with MDSA.

Treatment with MDSA can benefit OSA cases with improvement in nighttime sleep quality and daytime sleepiness, as assessed by reduction in AHI and ESS scores.

MDSA is a non-invasive, low risk and cost-effective treatment option for patients suffering from mild and moderate obstructive sleep apnea and also in cases of severe OSA who are not comfortable with CPAP or not willing for surgery provided that co-morbidities are carefully analyzed and patient compliance is adequate to achieve optimal results.

REFERENCES

16. Wilhelmsson B, Tegelberg Å, Walker-Engström ML,


